Calcineurin Inhibitors

ApprovedSmall molecule

Sanofi

Calcineurin Inhibitors is one of 209 small molecule programs targeting Kidney Transplant. It is currently in Approved.

Indications

Total Trials

Active Trials

208

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

PneumoniaActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

Atopic DermatitisActive, not recruiting

Prurigo NodularisActive, not recruiting

Renal InsufficiencyActive, not recruiting

Lung TransplantationActive, not recruiting

Kidney TransplantApproved

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

Interstitial Lung DiseasePreclinical

Active, not recruiting

Atopic DermatitisPhase 3

Active, not recruiting

Prurigo NodularisPhase 3

Active, not recruiting

Renal InsufficiencyPhase 3

Active, not recruiting

Lung TransplantationApproved

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Calcineurin Inhibitors

Sanofi

Approved

1 2

Jakafi

Incyte

Preclinical

1 3

Primaquine

Sanofi

Preclinical

1 4

Prevacid

Takeda

Preclinical

1 5

Innohep

Alnylam Pharmaceuticals

Preclinical

1 6

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 7

Advil

KKenvue Brands

Preclinical

2 8

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 9

Alka-Seltzer

AAbbott

Preclinical

1 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

Interstitial Lung Disease

NCT07406932

Clinical

Trials by Indication[1]

Prurigo Nodularis2 trials

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Completed· Sanofi logo

Sanofi·Phase 3·NCT04183335·151 enrolled

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

Completed· Sanofi logo

Sanofi·Phase 3·NCT04202679·160 enrolled

Post-Transplant Lymphoproliferative Disorder1 trial

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT01656343·775 enrolled

Interstitial Lung Disease1 trial

A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

Not yet recruiting·—·N/A·NCT07406932·80 enrolled

Renal Transplant Recipients1 trial

ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT00170846·394 enrolled

Atopic Dermatitis1 trial

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Completed· Sanofi logo

Sanofi·Phase 3·NCT06224348·643 enrolled

7 more indications

Lung Transplantation1 trial

Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

Completed· Novartis logo

Novartis·Phase 4·NCT00377962·282 enrolled

Renal insufficiency1 trial

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

Completed· Novartis logo

Novartis·Phase 3·NCT00267189·145 enrolled

Kidney Transplant1 trial

Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

Completed· Roche logo

Roche·Phase 4·NCT00121810·305 enrolled

Pneumonia1 trial

Basiliximab Treating Interstitial Pneumonia of CADM

Unknown status·RRenJi Hospital·Phase 2·NCT03192657·100 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Completed·RRegimmune Corporation·Phase 1/2·NCT01379209·68 enrolled

Monoclonal1 trial

MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02241018·200 enrolled

Dermatitis, Atopic1 trial

A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.

Enrolling by invitation· Sanofi logo

Sanofi·Preclinical·NCT05492578·1,663 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Calcineurin Inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calcineurin Inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calcineurin Inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Calcineurin Inhibitors

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Prurigo Nodularis2 trials

Post-Transplant Lymphoproliferative Disorder1 trial

Interstitial Lung Disease1 trial

Renal Transplant Recipients1 trial

Atopic Dermatitis1 trial

Lung Transplantation1 trial

Renal insufficiency1 trial

Kidney Transplant1 trial

Pneumonia1 trial

Hematopoietic Stem Cell Transplantation1 trial

Monoclonal1 trial

Dermatitis, Atopic1 trial

References

Drug Info

Quick Facts

Related News